|
Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies |
||||
| Nonsmoking |
Smoking |
|||
|
|
||||
| Cases/controls |
Relative risk (95% confidence interval) |
Cases/controls |
Relative risk (95% confidence interval) |
|
|
|
||||
| Anti-CCP antibody-positive |
||||
| HLA-shared epitope-positive |
33/41 |
1.00 |
71/49 |
1.67 (0.95–2.94) |
| HLA-shared epitope-negative |
62/33 |
2.05 (1.12–3.75) |
143/21 |
7.61 (4.05–14.30) |
| Anti-CCP antibody-negative |
||||
| HLA-shared epitope-positive |
40/41 |
1.00 |
52/49 |
1.11 (0.63–1.95) |
| HLA-shared epitope-negative |
23/33 |
0.71 (0.37–1.38) |
31/21 |
1.92 (0.98–3.77) |
|
The combination of carriage of HLA-shared epitope alleles or not, and ever or never smoking were compared for groups stratified for anti-CCP antibodies. | ||||
Kokkonen et al. Arthritis Research & Therapy 2007 9:R56 doi:10.1186/ar2214 |
||||